Community pharmacist targeted screening for chronic kidney disease

Abstract

Get full access to this article

View all access options for this article.

References

Arora

Vasa

Brenner

. Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. CMAJ 2013;185:E417-23.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3(1):1-150.

Zillich

Saseen

Dehart

. Caring for patients with chronic kidney disease: a joint opinion of the ambulatory care and the nephrology practice and research networks of the American College of Clinical Pharmacy. Pharmacotherapy 2005;25:123-42.

Jafar

Schmid

Landa

. Angiotensin converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.

Lewis

Hunsicker

Clarke

. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.

Wright

Jr Bakris

Greene

Agodoa

LY.

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 2002;288:2421-31.

Mitra

Bradley

JR.

Chronic kidney disease in primary care. J R Soc Med 2007;100:40-5.

Curtis

Balint

Al Hamarneh

. Online clinical pathway for managing adults with chronic kidney disease. Can Pharm J (Ott) 2015;148:257-62.

Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl 2013;3(3):1-305.

10.

Tobe

Stone

Brouwers

. Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE Initiative. CMAJ 2011;183:1135-50.

11.

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2013;37(Suppl 1):S1-212.

12.

Tanguay

J-F

Bell

Ackman

. Focused 2012 update of the Canadian Cardiovascular Society Guidelines for the use of antiplatelet therapy. Can J Cardiol 2013;29:1334-45.

13.

Anderson

Grégoire

Hegele

. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29:151-67.

14.

Hackam

Quinn

Ravani

. The 2013 Canadian Hypertension Education Program (CHEP) recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2013;29:528-42.

15.

Al Hamarneh

Jones

Hemmelgarn

Tsuyuki

. The Alberta vascular risk reduction community pharmacy project: RxEACH. 2015. Available: https://clinicaltrials.gov/ct2/show/NCT01979471 (accessed October 15, 2015).

16.

Statistics Canada. Annual demographic estimates: Canada, provinces and territories. Population by age and sex, 2013. Available: www.statcan.gc.ca/pub/91-215-x/2012000/part-partie2-eng.htm (accessed September 23, 2015).

17.

Szczech

Stewart

. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease). PLoS One 2014;9:e110535.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB